Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline’s ViiV Healthcare reports positive HIV drug data

GlaxoSmithKline’s ViiV Healthcare reports positive HIV drug data

16th September 2013

GlaxoSmithKline and Pfizer's joint venture ViiV Healthcare has reported positive data from a phase IIIb/IV trial assessing a new therapy for HIV-1.

The open-label Flamingo trial compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a protease inhibitor (PI) in treatment-naive adults with HIV-1.

It was found that ViiV Healthcare's drug resulted in a significantly greater proportion of the patients experiencing virological suppression, meaning the therapy exceeded the study's primary goal of non-inferiority.

Dr John Pottage, chief medical officer at ViiV Healthcare, said: "PIs are often selected as part of a first-line regimen for treatment-naive patients, so this data provides important information regarding dolutegravir as a treatment choice for these patients."

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline and Pfizer, with Shionogi taking a ten percent share in the firm last year.

Last month, the organisation received regulatory approval for dolutegravir in the US, where it will be sold under the brand name Tivicay.ADNFCR-8000103-ID-801637670-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.